As experts in radioisotopes,
we are committed to enhancing human health
and advancing medical care
News
-
-
2026.07.13Press ReleasePeptiDream Announces First Patient Dosed in Phase 1 Trial of First Wholly-Owned Radiopharmaceutical Program Targeting Carbonic Anhydrase IX (CA9) for Kidney Cancer（PeptiDream Inc. ）
-
2026.07.02Press ReleaseInitial Post-Dose Analysis Conducted in First Patient in First-in-Human Study of 64Cu-PD-29875, a Claudin18.2-Targeting Radiopharmaceutical Candidate（PeptiDream Inc.）
-
2026.07.01InformationAnnouncement of New Management Structure
-
2026.06.23InformationDr. Masato Murakami, President and Representative Director of the Company, Appointed President of the Japan Radiopharmaceuticals Association
-
2026.06.11Press ReleasePeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
-